Hi,
moomoo ID:NaN
Log Out
ENGLISH
  • ENGLISH
  • 中文繁体
  • 中文简体
donwloadimg

Download App

Log in to access Online Inquiry
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data
ARCT Arcturus Therapeutics
13.620
-0.400-2.85%
Post Mkt Price
13.6200.0000.00%
YOY
Do not show
Hide blank lines
(Q2)2022/06/30(Q1)2022/03/31(FY)2021/12/31(Q4)2021/12/31
Total revenue
1253.97% 27.09M 146.54% 5.24M 29.56% 12.36M 158.89% 5.79M
Operating revenue
1253.97% 27.09M 146.54% 5.24M 29.56% 12.36M 158.89% 5.79M
Cost of revenue
Gross profit
Operating expense
-11.74% 49.18M -6.97% 55.62M 165.49% 215.21M 30.37% 43.44M
Selling and administrative expenses
9.47% 10.99M 10.13% 10.73M 78.54% 41.45M 19.61% 10.81M
-General and administrative expense
9.47% 10.99M 10.13% 10.73M 78.54% 41.45M 19.61% 10.81M
Research and development costs
-16.4% 38.19M -10.3% 44.89M 200.38% 173.76M 34.37% 32.63M
Operating profit
58.88% -22.09M 12.64% -50.38M -183.61% -202.85M -21.12% -37.65M
Net non-operating interest income expense
-7.69% -560K -57.54% -564K -432.13% -1.92M -2281.82% -524K
Non-operating interest income
-11.58% 168K -18.09% 154K 60.21% 753K 8.88% 184K
Non-operating interest expense
2.54% 728K 31.5% 718K 221.78% 2.67M 270.68% 708K
Other net income (expense)
418.48% 1.09M -113.47% -226K 517.87% 1.1M -494K
Gain on sale of security
9461.54% 1.22M -63.26% 158K -- 584K -- -339K
Earnings from equity interest
60.06% -131K -130.77% -384K 295.82% 515K -- -155K
Income before tax
60.49% -21.56M 9.19% -51.17M -182.3% -203.67M -24.3% -38.66M
Income tax
Net income
60.49% -21.56M 9.19% -51.17M -182.3% -203.67M -24.3% -38.66M
Net income continuous Operations
60.49% -21.56M 9.19% -51.17M -182.3% -203.67M -24.3% -38.66M
Minority interest income
Net income attributable to the parent company
60.49% -21.56M 9.19% -51.17M -182.3% -203.67M -24.3% -38.66M
Preferred stock dividends
Other preferred stock dividends
Net income attributable to common stockholders
60.49% -21.56M 9.19% -51.17M -182.3% -203.67M -24.3% -38.66M
Basic earnings per share
60.39% -0.82 9.77% -1.94 -118.03% -7.74 -8.09% -1.47
Diluted earnings per share
60.39% -0.82 9.77% -1.94 -118.03% -7.74 -8.09% -1.47
Dividend per share
Currency Unit
USDUSDUSDUSD
Accounting Standards
US-GAAPUS-GAAPUS-GAAPUS-GAAP
Audit Opinions
----Unqualified Opinion--

FY: Financial Year Annual Report, which is equivalent to the 10-K file disclosed by the listed company to the SEC.

Q: Quarterly report, which is equivalent to the 10-Q file disclosed by the listed company to the SEC, where Q1, Q2, Q3, and Q4 are single quarterly reports with a span of 3 months; Q6 and Q9 are cumulative quarterly reports, and Q6 is 6 months , Q9 is 9 months.

The MOM data from the Quarterly report,MOM=(current period - last period)/last period *100%

Company Overview More
Arcturus Therapeutics Holdings, Inc. develops pharmaceuticals. It is a clinical-stage mRNA medicines and vaccines company, which focuses on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases. The firm's products include LUNAR-COV19, LUNAR-FLU, LUNAR-OTC, and LUNAR-CF. The company was founded in 2013 and is headquartered in San Diego, CA.
CEO: Mr. Joseph E. Payne
Market: NASDAQ
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...